Share Price and Basic Stock Data
Last Updated: December 10, 2025, 11:01 pm
| PEG Ratio | 1.68 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bacil Pharma Ltd operates in the pharmaceuticals sector, yet its revenue performance has been a notable point of concern. The company has reported a consistent lack of sales, with revenues standing at ₹0.00 across the last several quarters, including the most recent data up to March 2025. This stagnation raises questions about the company’s operational effectiveness and market positioning. Despite being in an industry ripe with opportunities, particularly in the wake of increased healthcare spending, Bacil Pharma seems unable to capitalize on these trends. The company’s expenses, while relatively low, have fluctuated slightly, indicating some level of operational activity, but without revenue generation, these costs translate into continuous operating losses. Investors may need to consider how Bacil plans to pivot its strategy or product offerings to generate revenue in the future.
Profitability and Efficiency Metrics
Profitability metrics for Bacil Pharma reflect a challenging scenario. The company reported a net profit of ₹1.11 Cr for the trailing twelve months, marking a significant improvement from previous periods where net losses were common. However, the P/E ratio is a staggering 91.9, suggesting that the stock is highly valued relative to its earnings. This could indicate overvaluation, especially given the absence of consistent sales. Efficiency ratios like Return on Equity (ROE) and Return on Capital Employed (ROCE) stand at 0.98% and 0.97% respectively. Such low returns suggest that the company is not generating sufficient profit relative to its equity and capital employed. While there was a modest net profit recorded recently, it is crucial for investors to monitor whether this trend can be sustained and improved upon in subsequent quarters.
Balance Sheet Strength and Financial Ratios
The balance sheet of Bacil Pharma shows a mix of strengths and weaknesses. On the one hand, the company has maintained a low level of borrowings, reported at just ₹0.16 Cr, which indicates a conservative capital structure. This could be a positive sign for risk-averse investors. However, the reserves have dramatically shifted from negative in previous years to ₹11.46 Cr, which is a positive development reflecting some retention of earnings. The current ratio stands at an impressive 17.64, suggesting that Bacil has ample liquidity to cover its short-term obligations. However, with a Price-to-Book Value (P/BV) ratio of 2.33x, the valuation seems stretched, particularly when weighed against the backdrop of ongoing operational losses. This imbalance raises questions about the sustainability of the current valuation in light of the company’s financial performance.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bacil Pharma has undergone significant changes, particularly in the recent quarters. Promoter holding has dramatically decreased from 42.67% in December 2022 to a mere 0.20% by March 2025, suggesting a significant exit by the promoters or a dilution of their stake. In contrast, public ownership has surged to 99.92%, indicating a shift in investor confidence, albeit with a lack of institutional backing as both Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) appear absent. This could reflect a mixed sentiment among investors; while the public seems willing to hold shares, the exit of promoters may raise red flags regarding the company’s future direction. The increase in the number of shareholders to 7,431 also suggests a growing interest, but it remains to be seen if this translates into long-term investor commitment.
Outlook, Risks, and Final Insight
Looking ahead, Bacil Pharma faces a challenging landscape. The absence of revenue generation poses a substantial risk, and while recent positive net profit figures may offer a glimmer of hope, they need to be viewed in the context of sustained operational performance. Investors should be cautious of the high P/E ratio, which implies that the stock is trading at a premium, potentially leaving little room for error. Moreover, the drastic reduction in promoter holding could signal deeper issues within the company or a lack of confidence from those who know it best. On the flip side, the healthy liquidity position and improved reserves could provide a buffer against short-term challenges. In summary, while Bacil Pharma has some strengths, the significant operational hurdles and shifting shareholder dynamics present substantial risks that investors should carefully weigh before considering an investment in the company.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Bacil Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 244/84.3 | 31.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,169 Cr. | 383 | 479/192 | 86.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.4 Cr. | 43.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 45.3 Cr. | 30.9 | 31.0/17.0 | 108 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,300.60 Cr | 1,152.20 | 52.34 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.05 | 0.04 | 0.04 | 0.09 | 0.03 | 0.04 | 0.05 | 0.06 | 0.04 | 0.07 | 0.06 | 0.07 | 0.11 |
| Operating Profit | -0.05 | -0.04 | -0.04 | -0.09 | -0.03 | -0.04 | -0.05 | -0.06 | -0.04 | -0.07 | -0.06 | -0.07 | -0.11 |
| OPM % | |||||||||||||
| Other Income | 0.07 | 0.04 | 0.00 | 0.01 | 0.05 | 0.03 | 0.03 | 0.02 | 0.01 | 0.56 | 0.00 | 0.09 | 1.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.02 | 0.00 | -0.04 | -0.08 | 0.02 | -0.01 | -0.02 | -0.04 | -0.03 | 0.49 | -0.06 | 0.02 | 0.89 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 24.72% | |
| Net Profit | 0.02 | 0.00 | -0.04 | -0.08 | 0.02 | -0.01 | -0.02 | -0.04 | -0.03 | 0.48 | -0.06 | 0.02 | 0.67 |
| EPS in Rs | 0.03 | 0.00 | -0.07 | -0.14 | 0.03 | -0.02 | -0.03 | -0.07 | -0.05 | 0.81 | -0.10 | 0.01 | 0.47 |
Last Updated: August 19, 2025, 10:45 pm
Below is a detailed analysis of the quarterly data for Bacil Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Jun 2025, the value is 0.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.07 Cr. (Mar 2025) to 0.11 Cr., marking an increase of 0.04 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.11 Cr.. The value appears to be declining and may need further review. It has decreased from -0.07 Cr. (Mar 2025) to -0.11 Cr., marking a decrease of 0.04 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.09 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 0.91 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.89 Cr.. The value appears strong and on an upward trend. It has increased from 0.02 Cr. (Mar 2025) to 0.89 Cr., marking an increase of 0.87 Cr..
- For Tax %, as of Jun 2025, the value is 24.72%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Mar 2025) to 24.72%, marking an increase of 24.72%.
- For Net Profit, as of Jun 2025, the value is 0.67 Cr.. The value appears strong and on an upward trend. It has increased from 0.02 Cr. (Mar 2025) to 0.67 Cr., marking an increase of 0.65 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.47. The value appears strong and on an upward trend. It has increased from 0.01 (Mar 2025) to 0.47, marking an increase of 0.46.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:50 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.09 | 0.11 | 0.13 | 0.17 | 0.29 | 0.26 | 0.18 | 0.16 | 0.16 | 0.17 | 0.19 | 0.25 | 0.31 |
| Operating Profit | -0.09 | -0.11 | -0.13 | -0.17 | -0.29 | -0.26 | -0.18 | -0.16 | -0.16 | -0.17 | -0.19 | -0.25 | -0.31 |
| OPM % | |||||||||||||
| Other Income | -0.01 | 0.08 | 0.06 | 0.17 | -3.42 | -0.07 | -0.12 | -0.07 | -3.70 | 0.07 | 0.13 | 0.66 | 1.65 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.11 | -0.03 | -0.07 | 0.00 | -3.75 | -0.34 | -0.32 | -0.23 | -3.86 | -0.10 | -0.06 | 0.41 | 1.34 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | -0.11 | -0.03 | -0.07 | 0.00 | -3.75 | -0.34 | -0.32 | -0.24 | -3.86 | -0.10 | -0.06 | 0.40 | 1.11 |
| EPS in Rs | -0.19 | -0.05 | -0.12 | 0.00 | -6.37 | -0.58 | -0.54 | -0.41 | -6.55 | -0.17 | -0.10 | 0.28 | 1.19 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 72.73% | -133.33% | 100.00% | 90.93% | 5.88% | 25.00% | -1508.33% | 97.41% | 40.00% | 766.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -206.06% | 233.33% | -9.07% | -85.05% | 19.12% | -1533.33% | 1605.74% | -57.41% | 726.67% |
Bacil Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 54% |
| 3 Years: | 82% |
| TTM: | 1210% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 64% |
| 3 Years: | 102% |
| 1 Year: | 69% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -1% |
| 3 Years: | 1% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:31 pm
Balance Sheet
Last Updated: October 10, 2025, 3:34 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 13.97 |
| Reserves | -0.03 | -0.06 | -0.13 | -0.09 | -4.29 | -4.62 | -5.14 | -5.14 | -5.30 | -5.43 | -5.31 | 11.46 |
| Borrowings | 0.08 | 0.14 | 0.27 | 0.31 | 0.00 | 0.10 | 0.17 | 0.18 | 0.03 | 0.02 | 0.10 | 0.16 |
| Other Liabilities | 0.01 | 0.02 | 0.02 | 0.02 | 2.51 | 2.55 | 2.55 | 2.52 | 0.01 | 0.01 | 0.01 | 0.02 |
| Total Liabilities | 6.59 | 6.63 | 6.69 | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 |
| Fixed Assets | 0.01 | 0.01 | 5.25 | 5.94 | 2.53 | 2.53 | 2.52 | 2.51 | 0.01 | 0.01 | 0.01 | 0.00 |
| CWIP | 5.80 | 5.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.25 | 0.51 | 0.51 | 0.54 | 1.15 | 0.96 | 0.43 | 0.37 | 0.31 | 0.43 | 0.61 | 21.36 |
| Other Assets | 0.53 | 0.23 | 0.93 | 0.29 | 1.07 | 1.07 | 1.16 | 1.21 | 0.95 | 0.69 | 0.71 | 4.25 |
| Total Assets | 6.59 | 6.63 | 6.69 | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 |
Below is a detailed analysis of the balance sheet data for Bacil Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 13.97 Cr.. The value appears strong and on an upward trend. It has increased from 6.53 Cr. (Mar 2024) to 13.97 Cr., marking an increase of 7.44 Cr..
- For Reserves, as of Mar 2025, the value is 11.46 Cr.. The value appears strong and on an upward trend. It has increased from -5.31 Cr. (Mar 2024) to 11.46 Cr., marking an increase of 16.77 Cr..
- For Borrowings, as of Mar 2025, the value is 0.16 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.10 Cr. (Mar 2024) to 0.16 Cr., marking an increase of 0.06 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.02 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.01 Cr. (Mar 2024) to 0.02 Cr., marking an increase of 0.01 Cr..
- For Total Liabilities, as of Mar 2025, the value is 25.61 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.33 Cr. (Mar 2024) to 25.61 Cr., marking an increase of 24.28 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.01 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 0.01 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 21.36 Cr.. The value appears strong and on an upward trend. It has increased from 0.61 Cr. (Mar 2024) to 21.36 Cr., marking an increase of 20.75 Cr..
- For Other Assets, as of Mar 2025, the value is 4.25 Cr.. The value appears strong and on an upward trend. It has increased from 0.71 Cr. (Mar 2024) to 4.25 Cr., marking an increase of 3.54 Cr..
- For Total Assets, as of Mar 2025, the value is 25.61 Cr.. The value appears strong and on an upward trend. It has increased from 1.33 Cr. (Mar 2024) to 25.61 Cr., marking an increase of 24.28 Cr..
Notably, the Reserves (11.46 Cr.) exceed the Borrowings (0.16 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.17 | -0.25 | -0.40 | -0.48 | -0.29 | -0.36 | -0.35 | -0.34 | -0.19 | -0.19 | -0.29 | -0.41 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | ||||||||||||
| Working Capital Days | ||||||||||||
| ROCE % | -0.61% | -0.45% | -1.05% | -1.49% | -6.01% | -8.47% | -2.80% | -5.75% | -7.07% | -12.61% | -13.11% | -0.97% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 |
| Diluted EPS (Rs.) | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 |
| Cash EPS (Rs.) | 0.28 | -0.08 | -0.15 | -5.91 | -0.35 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 18.20 | 1.86 | 1.68 | 1.88 | 2.13 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 18.20 | 1.86 | 1.68 | 1.88 | 2.13 |
| PBDIT / Share (Rs.) | 0.29 | -0.08 | -0.15 | -5.91 | -0.35 |
| PBIT / Share (Rs.) | 0.29 | -0.09 | -0.15 | -5.91 | -0.36 |
| PBT / Share (Rs.) | 0.29 | -0.09 | -0.15 | -5.91 | -0.36 |
| Net Profit / Share (Rs.) | 0.28 | -0.09 | -0.15 | -5.91 | -0.36 |
| Return on Networth / Equity (%) | 1.58 | -4.85 | -9.26 | -315.24 | -17.19 |
| Return on Capital Employeed (%) | 1.60 | -4.86 | -9.26 | -315.26 | -17.22 |
| Return On Assets (%) | 1.57 | -4.44 | -9.03 | -303.54 | -5.85 |
| Total Debt / Equity (X) | 0.01 | 0.08 | 0.01 | 0.02 | 0.12 |
| Current Ratio (X) | 17.64 | 0.46 | 8.19 | 10.63 | 1.04 |
| Quick Ratio (X) | 17.64 | 0.46 | 8.19 | 10.63 | 1.04 |
| Enterprise Value (Cr.) | 22.33 | 9.61 | 3.57 | 3.54 | 2.11 |
| EV / EBITDA (X) | 138.79 | -168.53 | -35.97 | -0.91 | -9.00 |
| Price / BV (X) | 2.33 | 7.87 | 3.25 | 3.06 | 1.46 |
| EarningsYield | 0.01 | -0.01 | -0.02 | -1.03 | -0.11 |
After reviewing the key financial ratios for Bacil Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 5. It has increased from -0.10 (Mar 24) to 0.64, marking an increase of 0.74.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 5. It has increased from -0.10 (Mar 24) to 0.64, marking an increase of 0.74.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 3. It has increased from -0.08 (Mar 24) to 0.28, marking an increase of 0.36.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.20. It has increased from 1.86 (Mar 24) to 18.20, marking an increase of 16.34.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.20. It has increased from 1.86 (Mar 24) to 18.20, marking an increase of 16.34.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 2. It has increased from -0.08 (Mar 24) to 0.29, marking an increase of 0.37.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from -0.09 (Mar 24) to 0.29, marking an increase of 0.38.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from -0.09 (Mar 24) to 0.29, marking an increase of 0.38.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 2. It has increased from -0.09 (Mar 24) to 0.28, marking an increase of 0.37.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 15. It has increased from -4.85 (Mar 24) to 1.58, marking an increase of 6.43.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.60. This value is below the healthy minimum of 10. It has increased from -4.86 (Mar 24) to 1.60, marking an increase of 6.46.
- For Return On Assets (%), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 5. It has increased from -4.44 (Mar 24) to 1.57, marking an increase of 6.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has decreased from 0.08 (Mar 24) to 0.01, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 17.64. This value exceeds the healthy maximum of 3. It has increased from 0.46 (Mar 24) to 17.64, marking an increase of 17.18.
- For Quick Ratio (X), as of Mar 25, the value is 17.64. This value exceeds the healthy maximum of 2. It has increased from 0.46 (Mar 24) to 17.64, marking an increase of 17.18.
- For Enterprise Value (Cr.), as of Mar 25, the value is 22.33. It has increased from 9.61 (Mar 24) to 22.33, marking an increase of 12.72.
- For EV / EBITDA (X), as of Mar 25, the value is 138.79. This value exceeds the healthy maximum of 15. It has increased from -168.53 (Mar 24) to 138.79, marking an increase of 307.32.
- For Price / BV (X), as of Mar 25, the value is 2.33. This value is within the healthy range. It has decreased from 7.87 (Mar 24) to 2.33, marking a decrease of 5.54.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.01, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bacil Pharma Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.6% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.58% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 17.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 91.4 (Industry average Stock P/E: 43.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | G2/G3, Samarpan Complex, Next To Mirador Hotel, Link Road, Mumbai Maharashtra 400099 | bacilpha@yahoo.com https://bacilpharma.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Chaitali Kalpataru Shah | Executive Director & CFO |
| Mr. Dinesh Chander Notiyal | Independent Director |
| Ms. Avani Savjibibhai Godhaniya | Independent Director |
FAQ
What is the intrinsic value of Bacil Pharma Ltd?
Bacil Pharma Ltd's intrinsic value (as of 10 December 2025) is 13.45 which is 67.03% lower the current market price of 40.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 58.5 Cr. market cap, FY2025-2026 high/low of 62.6/26.7, reserves of ₹11.46 Cr, and liabilities of 25.61 Cr.
What is the Market Cap of Bacil Pharma Ltd?
The Market Cap of Bacil Pharma Ltd is 58.5 Cr..
What is the current Stock Price of Bacil Pharma Ltd as on 10 December 2025?
The current stock price of Bacil Pharma Ltd as on 10 December 2025 is 40.8.
What is the High / Low of Bacil Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bacil Pharma Ltd stocks is 62.6/26.7.
What is the Stock P/E of Bacil Pharma Ltd?
The Stock P/E of Bacil Pharma Ltd is 91.4.
What is the Book Value of Bacil Pharma Ltd?
The Book Value of Bacil Pharma Ltd is 18.4.
What is the Dividend Yield of Bacil Pharma Ltd?
The Dividend Yield of Bacil Pharma Ltd is 0.00 %.
What is the ROCE of Bacil Pharma Ltd?
The ROCE of Bacil Pharma Ltd is 0.97 %.
What is the ROE of Bacil Pharma Ltd?
The ROE of Bacil Pharma Ltd is 0.98 %.
What is the Face Value of Bacil Pharma Ltd?
The Face Value of Bacil Pharma Ltd is 10.0.